Radiolabeled Therapeutic Agents for Personalized Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiological imaging techniques lack the ability to customize treatments effectively for individual patients, often relying on general bioavailability curves that fail to distinguish target cells from non-target cells, leading to inefficiencies and potential toxicity.
Innovation Solution
The use of radiolabeled therapeutic agents in combination with SPECT or PET imaging to optimize treatment by determining personalized dosages that maximize therapeutic effectiveness while minimizing adverse events, allowing for precise targeting of biological targets with low radiation exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If general bioavailability curves are used for dosing, then treatment can be applied broadly to patient populations, but treatment precision and ability to distinguish target cells from non-target cells deteriorates
Solution Approach 1:
A dosimetric infusion of radiolabeled therapeutic agent is administered before the main therapeutic treatment to perform in vivo dosimetry and imaging. This preliminary action allows measurement of actual biodistribution and radiation clearance rates in each patient, enabling personalized dosing calculations that precisely distinguish target cell uptake from non-target tissue accumulation before committing to the full therapeutic dose
Solution Approach 2:
The patent changes the dosing parameter from fixed population-based dosing to dynamic patient-specific dosing based on measured radiation clearance rates. By adjusting the therapeutic dose parameter according to individual patient biodistribution characteristics observed during dosimetry, the system achieves both efficient treatment delivery and precise target cell discrimination
2Reliability
If higher radiation doses are administered to maximize therapeutic effectiveness, then tumor treatment efficacy improves, but toxicity to non-target cells and adverse events increases
Solution Approach 1:
The system implements feedback through dosimetry imaging that measures actual radiation clearance rates and biodistribution in each patient. This feedback information is used to calculate and adjust the therapeutic dose parameter, ensuring the administered dose achieves maximum tumor effectiveness while staying within safety margins that prevent excessive toxicity to non-target cells
Solution Approach 2:
The patent applies local quality by delivering radiation dose according to local tissue characteristics and biodistribution patterns observed in each patient. The therapeutic agent concentration varies locally based on target cell uptake, and the dosing regimen is customized to account for local differences in radiation clearance between patients and between target and non-target tissues
3Adaptability or versatility
If radiolabeled therapeutic agents are used for both imaging and therapy, then treatment customization capability improves, but device complexity and dosing protocol complexity increases
Solution Approach 1:
The patent applies universality by using the same radiolabeled therapeutic agent for both imaging/dosimetry and therapeutic functions. The radiolabeled anti-CD20 antibody serves dual purposes: it enables visualization and measurement of biodistribution for dosimetry, and simultaneously provides the therapeutic effect when administered at higher doses, eliminating the need for separate diagnostic and therapeutic agents
Solution Approach 2:
The dosimetric infusion serves as a preliminary action that simplifies the overall protocol by providing all necessary biodistribution data before the main therapeutic administration. This single preliminary imaging dose captures the pharmacokinetic characteristics needed for personalized dosing calculation, avoiding the need for multiple separate imaging studies or complex monitoring protocols during therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables tailored treatment strategies that enhance therapeutic efficacy, reduce toxicity, and improve treatment outcomes by providing real-time biochemical activity data for customized dosing and monitoring of therapeutic effects and side effects.
Implementation Method 1
administering a radiolabeled form of a therapeutic agent... determining information related to a biodistribution of the radiolabeled form of the therapeutic agent in the patient by performing a radioimaging procedure
Data Source
AI summary
A method for treating a human patient is provided, including administering a radiolabeled form of a therapeutic agent to the patient at a first substantially non-therapeutically-effective dose, wherein pharmacological activity of the therapeutic agent is not due to radioactivity of the therapeutic agent. The method also includes determining information related to a biodistribution of the radiolabeled form of the therapeutic agent in the patient by performing a radioimaging procedure on the patient. Responsively to the information, a decision is made whether or not to treat the patient by administering the therapeutic agent to the patient. If the decision is made to treat the patient, the patient is treated by administering the therapeutic agent to the patient at a second therapeutically-effective dose. If the decision is made not to treat the patient, treatment of the patient with the therapeutic agent is withheld. Other embodiments are also described.